Bhargava Kandala
Overview
Explore the profile of Bhargava Kandala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armstrong A, Geva R, Chung H, Lemech C, Miller Jr W, Hansen A, et al.
Invest New Drugs
. 2024 May;
42(3):340-341.
PMID: 38767685
No abstract available.
2.
Armstrong A, Geva R, Chung H, Lemech C, Miller Jr W, Hansen A, et al.
Invest New Drugs
. 2024 Feb;
42(1):145-159.
PMID: 38324085
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit of CXCR2 inhibition in...
3.
Kandala B, Plock N, Chawla A, Largajolli A, Robey S, Watson K, et al.
EBioMedicine
. 2022 Oct;
84:104264.
PMID: 36182824
Background: The COVID-19 pandemic has increased the need for innovative quantitative decision tools to support rapid development of safe and efficacious vaccines against SARS-CoV-2. To meet that need, we developed...
4.
Hochhaus G, Chen M, Kurumaddali A, Schilling U, Jiao Y, Drescher S, et al.
AAPS J
. 2021 Nov;
24(1):1.
PMID: 34811595
No abstract available.
5.
Schurmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman E, Robberechts M, et al.
J Acquir Immune Defic Syndr
. 2021 Oct;
89(2):191-198.
PMID: 34654041
Background: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support...
6.
Vaddady P, Kandala B
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(11):1323-1331.
PMID: 34319009
ModVizPop is an interactive and dynamic visualization tool developed for simulating differential equation-based population pharmacokinetic (PK) and pharmacodynamic (PD) models with variability. It has a built-in PK/PD ordinary differential equations...
7.
Hochhaus G, Chen M, Kurumaddali A, Schilling U, Jiao Y, Drescher S, et al.
AAPS J
. 2021 Mar;
23(3):48.
PMID: 33768368
In the context of streamlining generic approval, this study assessed whether pharmacokinetics (PK) could elucidate the pulmonary fate of orally inhaled drug products (OIDPs). Three fluticasone propionate (FP) dry powder...
8.
Vaddady P, Kandala B, Yee K
Antimicrob Agents Chemother
. 2020 Sep;
64(11).
PMID: 32868326
Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was...
9.
Visser S, Kandala B, Fancourt C, Krug A, Cho C
Clin Pharmacol Ther
. 2020 Jan;
107(6):1296-1311.
PMID: 31889297
A model-informed drug discovery and development strategy played a key role in the novel glucose-responsive insulin MK-2640's early clinical development strategy and supported a novel clinical trial paradigm to assess...
10.
Greaves W, Wan H, Yee K, Kandala B, Vaddady P, Hwang C
Antimicrob Agents Chemother
. 2019 Sep;
63(12).
PMID: 31548188
Doravirine is a non-nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after stopping...